Your browser doesn't support javascript.
loading
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds, Lynn; Linden, Hannah; Gadi, Vijayakrishna; Korde, Larissa; Rodler, Eve; Gralow, Julie; Redman, Mary; Baker, Kelsey; Wu, Quan Vicky; Jenkins, Isaac; Kurland, Brenda; Garrison, Mitchell; Smith, Julie; Anderson, Jeanne; Van Haelst, Carol; Specht, Jennifer.
Afiliação
  • Symonds L; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.
  • Linden H; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Gadi V; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Korde L; National Cancer Institute, Rockville, MD.
  • Rodler E; Division of Oncology and Hematology, Department of Internal Medicine, UC Davis Health, Sacramento, CA.
  • Gralow J; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Redman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Baker K; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Wu QV; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Jenkins I; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Kurland B; University of Pittsburgh, Pittsburgh, PA.
  • Garrison M; Confluence Health at Wenatchee Valley, Wenatchee, WA.
  • Smith J; Confluence Health at Wenatchee Valley, Wenatchee, WA.
  • Anderson J; Katmai Oncology Group, Anchorage, AK.
  • Van Haelst C; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.
  • Specht J; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: jspecht@uw.edu.
Clin Breast Cancer ; 19(2): e283-e296, 2019 04.
Article em En | MEDLINE | ID: mdl-30737173
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Inibidores da Angiogênese / Inibidores de Proteínas Quinases / Albuminas / Neoplasias de Mama Triplo Negativas / Cloridrato de Erlotinib / Bevacizumab Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Inibidores da Angiogênese / Inibidores de Proteínas Quinases / Albuminas / Neoplasias de Mama Triplo Negativas / Cloridrato de Erlotinib / Bevacizumab Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de publicação: Estados Unidos